Antitumor function of the immune system has been harnessed to eradicate tumor cells as cancer therapy. Therapeutic cancer vaccines aim to help immune cells recognize tumor cells, which are difficult to target owing to immune escape. Many attempts at vaccine designs have been conducted throughout the last decades. In addition, as the advanced understanding of immunosuppressive mechanisms mediated by tumor cells, combining cancer vaccines with other immune therapies seems to be more efficient for cancer treatment. Acute myeloid leukemia (AML) is the most common acute leukemia in adults with poor prognosis. Evidence has shown T-cell-mediated immune responses in AML, which encourages the utility of immune therapies in AML. This review discusses cancer vaccines in AML from vaccine design as well as recent progress in vaccination combination with other immune therapies.
Keywords: acute myeloid leukemia; cancer vaccine; combined immunotherapies; immunotherapy.
Lay abstract Acute myeloid leukemia (AML) is the most common acute leukemia in adults with poor prognosis. Evidence has shown that the immune system can recognize and eradicate AML cells. Immunotherapy, which aims at enhancing this antitumor function, emerges as a powerful cancer therapy. Cancer vaccine, one of the immunotherapies, helps the immune system recognize tumor cells. The treatment strategy has been explored in AML patients throughout the last decades. This review was a brief introduction of the development and design principle of cancer vaccine in AML. Moreover, we also demonstrated recent progress in vaccination combination with other immune therapies.